The Pathogenesis and Treatment of COVID-19: A System Review.
作者信息
Ji Ye Long, Wu Yang, Qiu Zhen, Ming Hao, Zhang Yi, Zhang Ai Ning, Leng Yan, Xia Zhong Yuan
机构信息
Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.
出版信息
Biomed Environ Sci. 2021 Jan 20;34(1):50-60. doi: 10.3967/bes2021.007.
Abstract
摘要
相似文献
1
The Pathogenesis and Treatment of COVID-19: A System Review.新型冠状病毒肺炎的发病机制与治疗：一项系统综述
Biomed Environ Sci. 2021 Jan 20;34(1):50-60. doi: 10.3967/bes2021.007.
2
The Responses of Biobanks to COVID-19.生物样本库对新冠疫情的应对措施。
Biopreserv Biobank. 2020 Dec;18(6):483-491. doi: 10.1089/bio.2020.29074.mkh. Epub 2020 Aug 31.
3
The Need for a Global Network to Cope with Pandemics from Studies of the COVID Infection.从新冠病毒感染研究看建立全球网络应对大流行的必要性
Monoclon Antib Immunodiagn Immunother. 2020 Oct;39(5):157-159. doi: 10.1089/mab.2020.29002.tke. Epub 2020 Sep 30.
4
Rapid deployment of pathology services to a remote Australian quarantine setting during the COVID-19 pandemic.在新冠疫情期间，将病理服务迅速部署到澳大利亚偏远的检疫场所。
Pathology. 2020 Dec;52(7):821-823. doi: 10.1016/j.pathol.2020.06.003. Epub 2020 Jul 10.
5
COVID-19 and Strategies for Its Therapeutics.COVID-19 与治疗策略。
Crit Rev Immunol. 2020;40(6):513-526. doi: 10.1615/CritRevImmunol.2020035633.
6
Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic.慢性淋巴细胞白血病患者的免疫功能障碍及 COVID-19 大流行期间的挑战
Acta Haematol. 2021;144(5):508-518. doi: 10.1159/000514071. Epub 2021 Feb 25.
7
Editorial: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), COVID-19 and cancer: three research questions casting a long shadow.社论：严重急性呼吸综合征冠状病毒2（SARS-CoV-2）、2019冠状病毒病（COVID-19）与癌症：三个影响深远的研究问题
Curr Opin Oncol. 2021 Mar 1;33(2):146-148. doi: 10.1097/CCO.0000000000000715.
8
A rational approach to COVID-19.对 COVID-19 的理性应对。
Hum Genomics. 2020 Dec 22;14(1):47. doi: 10.1186/s40246-020-00300-5.
9
Understanding and tracking the impact of long COVID in the United Kingdom.了解并追踪英国长期新冠的影响。
Nat Med. 2022 Jan;28(1):11-15. doi: 10.1038/s41591-021-01591-4.
10
COVID-19 in patients with cancer: managing a pandemic within a pandemic.癌症患者中的 COVID-19：在大流行中管理大流行。
Nat Rev Clin Oncol. 2021 Jan;18(1):1-2. doi: 10.1038/s41571-020-00441-5.
引用本文的文献
1
Human Endogenous Retrovirus (HERV) Transcriptome Is Dynamically Modulated during SARS-CoV-2 Infection and Allows Discrimination of COVID-19 Clinical Stages.人类内源性逆转录病毒（HERV）转录组在 SARS-CoV-2 感染过程中动态调节，并可区分 COVID-19 临床阶段。
Microbiol Spectr. 2023 Feb 14;11(1):e0251622. doi: 10.1128/spectrum.02516-22. Epub 2023 Jan 5.
2
A Case Series of Olfactory Dysfunction in Imported COVID-19 Patients: A 12-Month Follow-Up Study.进口 COVID-19 患者嗅觉功能障碍的病例系列：一项为期 12 个月的随访研究。
Biomed Environ Sci. 2022 May 20;35(5):402-411. doi: 10.3967/bes2022.056.
3
Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic.与 COVID-19 大流行相关的 SARS-CoV-2 的免疫反应和潜在治疗策略。
Int J Biol Sci. 2022 Feb 14;18(5):1865-1877. doi: 10.7150/ijbs.66369. eCollection 2022.
4
Factors Defining the Development of Severe Illness in Patients with COVID-19: A Retrospective Study.定义 COVID-19 患者发生重症疾病的因素：一项回顾性研究。
Biomed Environ Sci. 2021 Dec 20;34(12):984-991. doi: 10.3967/bes2021.117.
5
COVID-19 Vaccines for HIV-Infected Patients.COVID-19 疫苗对 HIV 感染者的影响。
Viruses. 2021 Sep 22;13(10):1890. doi: 10.3390/v13101890.
本文引用的文献
1
D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis.D-二聚体和凝血酶原时间是严重 COVID-19 和不良预后的重要指标。
Biomed Res Int. 2020 Jun 16;2020:6159720. doi: 10.1155/2020/6159720. eCollection 2020.
2
Corrigendum to "Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents" [J Hosp Infect 104 (2020) 246-251].《关于“冠状病毒在无生命表面的持久性及其被消毒剂灭活”的勘误》[《医院感染杂志》104 (2020) 246 - 251]
J Hosp Infect. 2020 Jun 17;105(3):587. doi: 10.1016/j.jhin.2020.06.001.
3
Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.评估磷酸二酯酶4（PDE4）抑制作用以减轻新型冠状病毒肺炎及其他疾病严重炎症的理论依据。
Isr Med Assoc J. 2020 Jun;22(6):335-339.
4
Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series.静脉注射免疫球蛋白（IVIG）治疗重症 COVID-19 患者的康复：病例系列。
Virology. 2020 Sep;548:1-5. doi: 10.1016/j.virol.2020.05.006. Epub 2020 May 25.
5
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.一种基于重组腺病毒 5 型的 COVID-19 疫苗的安全性、耐受性和免疫原性：一项剂量递增、开放标签、非随机、首次人体试验。
Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22.
6
Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.免疫调节疗法治疗重症 COVID-19。超越抗病毒治疗：全面综述。
Autoimmun Rev. 2020 Jul;19(7):102569. doi: 10.1016/j.autrev.2020.102569. Epub 2020 May 3.
7
How Big Data and Artificial Intelligence Can Help Better Manage the COVID-19 Pandemic.大数据和人工智能如何帮助更好地管理 COVID-19 大流行。
Int J Environ Res Public Health. 2020 May 2;17(9):3176. doi: 10.3390/ijerph17093176.
8
Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.生物制剂增加了感染 SARS-CoV-2 和住院的风险，但不会增加 ICU 收治和死亡的风险：在红色区域宣布期间来自大型队列的真实数据。
Dermatol Ther. 2020 Sep;33(5):e13475. doi: 10.1111/dth.13475. Epub 2020 May 19.
9
Comprehensive update on current outbreak of novel coronavirus infection (2019-nCoV).新型冠状病毒感染（2019-nCoV）当前疫情的全面更新。
Ann Transl Med. 2020 Mar;8(6):393. doi: 10.21037/atm.2020.02.92.
10
The importance of naturally attenuated SARS-CoV-2in the fight against COVID-19.自然减毒的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在抗击2019冠状病毒病（COVID-19）中的重要性。
Environ Microbiol. 2020 Jun;22(6):1997-2000. doi: 10.1111/1462-2920.15039.
Zotero 插件